The global ROCKET AF phase III trial evaluated rivaroxaban 20 mg once daily (o.d.) for stroke prevention in atrial fibrillation (AF). Based on rivaroxaban pharmacokinetics in Japanese subjects and lower anticoagulation preferences in Japan, particularly in elderly patients, the optimal dose regimen for Japanese AF patients was considered. The aim of this analysis was dose selection for Japanese patients from a pharmacokinetic aspect by comparison of simulated exposure in Japanese patients with those in Caucasian patients. As a result of population pharmacokinetics-pharmacodynamics analyses, a one-compartment pharmacokinetic model with first-order absorption and direct link pharmacokinetic-pharmacodynamic models optimally described the plasma concentration and pharmacodynamic models (Factor Xa activity, prothrombin time, activated partial thromboplastin time, and HepTest), which were also consistent with previous works. Steady-state simulations indicated 15 mg rivaroxaban o.d. doses in Japanese patients with AF would yield exposures comparable to the 20 mg o.d. dose in Caucasian patients with AF. In conclusion, in the context of the lower anticoagulation targets in Japanese practice, the population pharmacokinetic and pharmacodynamic modeling supports 15 mg o.d. as the principal rivaroxaban dose in J-ROCKET AF.
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and it is predicted that AF will affect over 1 million Japanese adults by 2030. 1) AF is an independent risk factor for stroke that carries a 2.8-and 3.7-fold excess risk for Japanese women and men, respectively.
2) The risk of stroke in patients with AF increases with age, 1.5-fold per decade.
3) Because Japan has one of the most rapidly ageing populations in the world, 4, 5) the economic burden imposed on Japanese healthcare systems by stroke is expected to become a critical issue. 6) As AF is responsible for approximately 15% of all strokes, 7) reducing AF-related stroke will clearly mitigate a significant portion of this burden.
Vitamin K antagonists (VKAs), such as warfarin, have been the mainstay of oral anticoagulant therapy. 8) Japanese guidelines, like others, 7, 9, 10) advocate the use of warfarin for stroke prevention in patients with AF and a moderate to high risk of stroke. 11) These guidelines reflect the benefit-risk analyses of Yasaka and others, 12, 13) in which elderly patients aged over 70 years were recommended to receive warfarin therapy to a lower target international normalized ratio (INR) level. Consequently, the guidelines recommend that warfarin be dose adjusted to an INR range of 2.0-3.0 in patients aged under 70 years and to an INR range of 1.6-2.6 for patients aged 70 years or older. 11) Registry data suggest that Japanese clinicians indeed seek lower INR targets in practice, and that lower targets are sought irrespective of age. 14) Warfarin use is complicated by multiple issues, including a variable dose response and numerous drug and food interactions, necessitating inconvenient regular clinic visits for INR monitoring and dose adjustment. 15) For these reasons, and despite guideline recommendations for its use in patients with AF at a moderate to high risk of stroke, 7, [9] [10] [11] warfarin is often under-prescribed to eligible patients. 16, 17) Given the considerable limitations of VKA therapy, a number of new oral anticoagulants that eliminate many of the drawbacks associated with VKAs 15) have been developed. Many of these are either in, 18, 19) or have completed, [20] [21] [22] [23] phase III trials for stroke prevention in patients with AF.
Rivaroxaban is an oral, direct Factor Xa inhibitor currently in development for the prevention of stroke in AF. Rivaroxaban has a dual mode of elimination: approximately one-third of the drug is eliminated unchanged via the kidneys; two-thirds of the drug undergoes metabolic degradation in the liver, half of which is excreted via the kidneys and half via the hepatobiliary route. 24) In previous phase I dose-ranging clinical studies, rivaroxaban has been found to have predictable pharmacokinetics and pharmacodynamics. 25, 26) Maximum inhibition of Factor Xa activity and maximum prolongation of prothrombin time (PT), activated partial thromboplastin time (aPTT) and HepTest, which has been developed to monitor anticoagulant effect of heparin and especially low molecular weight heparins, occurred within 1-4 h of administration of rivaroxaban. No accumulation of drug was found beyond steady state in a multiple-dose study. 26) A population pharmacokinetic and pharmacodynamic evaluation based on data obtained from phase IIb studies in patients undergoing major orthopaedic surgery given rivaroxaban once daily (o.d.) or twice daily (b.i.d.) reiterated the predictable pharmacokinetics of rivaroxaban. 27, 28) It was previously determined in phase II dose-ranging studies of rivaroxaban for deep vein thrombosis (DVT) treatment, conducted primarily in Caucasians, that 20 mg o.d. was a suitable dose for the prevention of recurrence of DVT 29, 30) ; this dataset informed the choice of a 20 mg o.d. dose for evaluation for stroke prevention in AF in the global ROCKET AF trial.
The global ROCKET AF trial tested a 20 mg dose of rivaroxaban (reduced to 15 mg in patients with creatinine clearance [CrCl] 30-49 ml min ¹1 ), in 45 countries, including countries in Asia other than Japan. 23) A lower dose of rivaroxaban was explored as possibly being more appropriate for use in Japan to accommodate: (1) phase I studies with rivaroxaban in healthy Japanese subjects (data on file), which showed a 20-40% increase in area under the plasma concentration-time curve (AUC) and a 20-30% increase in maximum plasma concentration (C max ) compared with phase I studies in healthy Caucasian subjects 26) ; (2) the unique aspects of Japanese clinical practice, i.e. the lower intensity of warfarin anticoagulation recommended in Japanese guidelines for older patients; (3) the relatively lower body mass indices of the Japanese population compared with populations of other countries, 31) a demographic known to be associated with higher drug exposures (previously described for ximelagatran 32, 33) ).
Although the 20 mg rivaroxaban dose was well tolerated in the Japanese phase I trials, phase II studies with Japanese AF patients conducted prior to the phase III study in Japanese AF patients were performed to see if a lower dose of rivaroxaban would be more suitable to test in the Japanese phase III J-ROCKET AF trial in light of expected higher exposure and the lower anticoagulation preferences in Japan. These phase II studies focused on the pharmacokinetics-pharmacodynamics (PK-PD) and safety of rivaroxaban in Japanese AF patients.
The study aimed to select an optimal dose regimen for Japanese AF patients in terms of pharmacokinetics employing the result of a comparison of simulated steady-state area under the curve (AUC ss ) and maximum concentration (C max,ss ) in Japanese patients with AF given rivaroxaban as 20 mg or 15 mg o.d. regimens (using a population pharmacokinetic model from the Japanese AF data in phase II trials) with a previously described virtual population of Caucasian patients with AF given rivaroxaban 20 mg o.d. (using a population pharmacokinetic model from Caucasian patients being treated for DVT). 34) This study also evaluated the inter-and intra-individual variability in the derived pharmacokinetic and pharmacodynamic parameters of rivaroxaban.
The phase II studies used for this analysis are the first studies with AF patients in order to investigate the pharmacokinetics, pharmacodynamic effects and safety of rivaroxaban in Japanese subjects with atrial fibrillation, and this study is the first population PK-PD evaluation of rivaroxaban in patients with AF, whose results could be used for appropriate dose setting in the Japanese phase III trial.
Methods
Study design and patient selection: Three Japanese phase II trials provided the data for this analysis. The number of subjects with pharmacokinetic and pharmacodynamic data in the three studies (denoted A, B and C) were A (36 subjects), B (72 subjects) and C (74 subjects). These were all open-label, doseranging studies that assessed the safety, pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular AF treated for 28 days. In these trials, the following rivaroxaban doses and dosing regimens were investigated: 2. The number of subjects, data availability and gender ratios for each dosing regimen from the three trials are listed in Table 1 . All three trials had similar durations, blood sampling times for pharmacokinetic and pharmacodynamic analyses, and inclusion and exclusion criteria. Japanese male patients aged ²20 years and postmenopausal female patients with electrocardiographically documented non-valvular AF (¯30 days before randomization) were enrolled. Patients had one or more of the following risk factors for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, heart failure or age ²60 years; thus most patients had a CHADS 2 score of 1 or above, which was the score for risk stratification for stroke prevention in patients with atrial fibrillation, 35) although patients with a CHADS 2 score of 0 were included in the three phase II studies ( Table 2) . Reasons for exclusion included a history or presence of stroke or transient ischaemic attack, or planned cardioversion or active endocarditis. Active internal bleeding, or a prior or active condition associated with increased bleeding (e.g., thrombocytopenia or persistent, poorly controlled hypertension); treatment with anticoagulant therapy within 1 week of randomization; liver cirrhosis/impaired liver function (transaminases or total bilirubin >2 © upper limit of normal [ULN]); or impaired renal function (serum creatinine >1.5 © ULN) were also exclusion criteria. Study participant demographics are listed in Table 3 . The mean age of the subjects was 65.6 years (range: 30-92 years) and mean body weight was 67.2 kg (range: 45-103 kg).
All subjects in these studies provided written, informed consent, and these studies were performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Sampling and determination of plasma rivaroxaban concentrations: Blood samples for pharmacokinetic and pharmacodynamic analyses were taken simultaneously except at baseline at the time points described in Figure 1 . Actual sampling time was Values obtained at the time of screening were used Albumin (g dl Values obtained at the time after dosing on Day 28 All covariates excluding height were tested for inclusion in the pharmacokinetic and pharmacodynamic model. d Creatinine clearance (CrCl) was calculated with the use of the Cockcroft-Gault formula. e The covariates on day 28 were coded as COV1 (e.g. ALB1) to distinguish from the value at baseline. BUN, blood urea nitrogen; SD, standard deviation; SGOT (AST), serum glutamic oxaloacetic transaminase (aspartate aminotransferase); SGPT (ALT), serum glutamic pyruvic transaminase (alanine aminotransferase). employed for analysis. Plasma rivaroxaban was extracted and concentrations were measured using a fully validated high performance liquid chromatography/tandem mass spectrometer (HPLC/ MS-MS) method (Agilent system 1100 coupled with an Applied Biosystems MDS Sciex API 3000 tandem mass spectrometer) as described previously. 36) Concentrations above the lower limit of quantification (LLOQ; 0.500 µg l
¹1
) were determined with a precision of 2.00-11.50% and 3.41-7.90% (intra-and inter-assay, respectively) and an accuracy of 94.0-105.0% and 96.3-102.3% (intra-and inter-assay, respectively).
Pharmacodynamic assays: Factor Xa activity, PT, aPTT and HepTest were used as pharmacodynamic parameters. PT and aPTT examine the effects of drugs on coagulation stimulated by the extrinsic and intrinsic clotting pathways, respectively. HepTest is used to monitor anticoagulation with LMWHs, and it measures Factor Xa activity indirectly.
These pharmacodynamic parameters were determined using methods described previously. 37) Briefly, Factor Xa activity was determined using a two-step photometric assay: total Factor X in plasma was activated to Factor Xa using Russell's viper venom in the presence of calcium ions. Subsequently, a chromogenic substrate (S-2765; Chromogenix, Milan, Italy) was hydrolyzed by Factor Xa, releasing p-nitroaniline, which was quantified by spectrophotometry at 405 nm. PT was determined using freeze-dried thromboplastin derived from rabbit brain (Neoplastin Plus μ ; Roche Diagnostics, Mannheim, Germany), with an International Sensitivity Index of 1.2. aPTT was assessed using a kaolin-activated test (Roche Diagnostics). PT, aPTT and HepTest (Haemachem, St. Louis, MO, USA) were measured with a ball coagulometer KC 10 (Amelung, Germany) as per the manufacturer's instructions.
Population pharmacokinetic and pharmacodynamic modeling: Population pharmacokinetic and pharmacodynamic analyses were performed separately, using non-linear mixed-effects modeling (NONMEM) version V level 1.1 (GloboMax LLC, Hanover, MD, USA) running in a validated Linux server farm environment. Separate models were developed for each set of pharmacodynamic data (Factor Xa, PT, aPTT and HepTest). The first-order conditional estimation with interaction method (FOCE-INTERACTION) was used for all analyses. All statistics and graphs were generated using S-Plus version 6 (Tibco Software Inc, Palo Alto, CA, USA) or SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).
The covariates that had a significant influence on a pharmacokinetic and pharmacodynamic parameter were determined using the output from the NONMEM post hoc estimation step.
Pharmacokinetic models: The population pharmacokinetic model (including all relevant covariates for the population) was established based on actual time of blood sampling relative to the rivaroxaban dose and amount, plasma concentrations and the demographic data of the study population. Both one-and twocompartment models were tested during model selection.
Pharmacodynamic models: The matched pharmacokinetic and pharmacodynamic data (including baseline data, where pharmacokinetic data were regarded as 0) were employed for analysis. Variables for the population pharmacodynamic model included measured plasma concentration, pharmacodynamic parameters and demographic data. Previously characterized models 25, 28, 34) were used as the starting model for all pharmacodynamic parameters.
Prothrombin time (PT)
Introduction of the parameter FACT (the exponent factor of plasma rivaroxaban concentration) improved the fit in the model that describes the relationship between plasma concentration and PT value.
Activated partial thromboplastin time (aPTT)
Introduction of FACT improved the fit in the model that described the relationship between plasma concentration and aPTT value.
HepTest
Introduction of the Hill coefficient, which is also an exponent factor of plasma concentration, improved the fit in the model that described the relationship between plasma concentration and HepTest value.
Factor Xa activity
As with the HepTest model, introduction of the Hill coefficient improved the fit in the model to describe the relationship between plasma concentration and Factor Xa activity.
Model development: The pharmacokinetic and pharmacodynamic model structures were optimized with the goal of reducing any unexplained variability. Covariates were incorporated into the models if the likelihood ratio test (LRT) showed a reduction in objective function value (OFV) of >6.63 (in the case of one degree of freedom [df]). After backwards removal from the full model, components were retained if the LRT showed a change in OFV of >10.8 (in the case of one df). A decrease by >6.63 or >10.8 points between competing models corresponds to prespecified nominal P values of <0.01 and <0.001, respectively. In addition to goodness-of-fit (GOF) statistics using the LRT, GOF 
graphs were also inspected to judge the adequacy of the model. To cover for the residual variability not reflected by the population model, additional error, proportional error and combined error models were tested, whose error models were selected based on evaluation of objective function values and GOF plots.
Furthermore, the final pharmacokinetic and pharmacodynamic models were also validated by visual predictive check (VPC) and a non-parametric bootstrap method to check the distributions of parameters.
Prediction and simulation: One thousand virtual Japanese patients with AF were simulated using the data from these three phase II pharmacokinetic-pharmacodynamic studies conducted in patients residing in Japan with AF (Tables 1, 2 and 3) and the results of an epidemiological investigation of the demographics of Japanese patients with AF, 38) which generated the ratio of male to female patients used in the simulation. Data regarding the covariate blood urea nitrogen (BUN) were generated for each gender by resampling the data from the three phase II studies. The resultant simulated patient population was used in the final population model to estimate individual exposure levels and pharmacodynamic parameters at steady state.
Simulation of virtual Caucasian patients with AF receiving 20 mg o.d. rivaroxaban has been described previously. 34) In brief, the simulation was based on the data from two phase II doseranging trials of rivaroxaban for treatment of DVT, 29, 30) with the demographics modified to reflect patients with AF enrolled in trials of ximelagatran. 39, 40) US epidemiology and phase I rivaroxaban data were employed to describe the relationship between age and renal function. 41, 42) Descriptive statistics of steady-state AUC 0-24h and C max were compared between the virtual Caucasian patients with AF receiving 20 mg rivaroxaban o.d. and the virtual Japanese patients with AF receiving 20 mg or 15 mg rivaroxaban o.d.
Results
Number of patients and pharmacokinetic and pharmacodynamic data points: A total of 182 subjects resident in Japan (148 men, 34 women) provided data for the population pharmacokinetic and pharmacodynamic analyses giving 842 data points for pharmacokinetic evaluation. For pharmacodynamic evaluations (including the additional baseline data), 987 data points were obtained for both PT and HepTest, 986 for aPTT and 985 for Factor Xa.
Pharmacokinetic model: Of the one-and two-compartment pharmacokinetic models that were tested during the model-building process, a one-compartment model with first-order absorption and proportional error model was found to optimally describe the plasma concentration versus time profile data taking into account the sparse sampling approach used in these clinical studies ( Fig. 2A) , consistent with previous pharmacokinetic modeling in Caucasians. 27, 28, 34) The final population estimates for pharmacokinetic parameters, such as the oral absorption rate constant (Ka), clearance (CL) and volume of distribution (V), are shown in Table 4 ; the residual (unexplained) variability of the model was 40.2%. Relative bioavailability (F1) was introduced and estimated at 24.4% to describe inter-individual variability from the population F1 mean, which was defined as 1.0. GOF graph examples with both population predictions and individual predictions are shown in Figures 3A and 3B .
On the basis of empirical Bayes estimate plots, the following covariates in the full population pharmacokinetic model were selected for evaluation: body surface area (BSA) and BUN for CL, lean body mass (LBM) for Ka, LBM for V, and serum glutamic pyruvic transaminase (SGPT) for F1. Each covariate was tested separately during the backward elimination process and BUN was the only covariate that remained in the model after this step. BUN, blood urea nitrogen; CL, apparent total clearance after oral administration; EC 50 , concentration resulting in half of the maximum effect; E max , maximum effect; F1, relative bioavailability; ©, random effect parameters for inter-individual variability; FACT, exponent factor for plasma concentration; Ka, oral absorption rate constant; V, apparent volume of distribution after oral administration.
CL was predicted to decrease/increase by 31.8% and 16.1%, respectively, when comparing a mean subject to the upper/lower ends of the demographic distribution in the dataset that was used for this evaluation (BUN lower end: 7.0 mg dl ). According to the population pharmacokinetic model, the magnitude of moderate or severe renal impairment (represented by BUN) would be expected to have a demonstrable impact on the pharmacokinetics of rivaroxaban.
Pharmacodynamic models: Prothrombin time (PT)
The selected base model consisted of a direct link combined power plus a linear model with proportional error model. On the basis of plots of empirical bayesian estimates, no covariates in the full population PT model were selected. As final model, a direct link combined power plus linear model with proportional error model was found to best fit the study data (Fig. 2B) . The baseline PT in the study population was 13.7 s and the slope of the correlation between PT and rivaroxaban concentration was 0.0227 s0l µg ¹1 ( Table 4) . No covariates exhibited a statistically significant effect on PT prolongation. Examples of GOF graphs are shown in Figures 3C and 3D .
Activated partial thromboplastin time (aPTT)
The selected base model consisted of a direct link combined power plus a linear model with proportional error model. On the basis of plots of empirical bayesian estimates, no covariates in full population aPPT model were selected. As final model, a direct link combined power plus linear model with proportional error model was found to fit the study data best (Fig. 2B) . The baseline aPTT in the study population was 32.6 s and the slope of the correlation between aPTT and rivaroxaban concentration was 0.0658 s0l µg ¹1 (Table 4) . No covariates exhibited a statistically significant effect on aPTT prolonging properties. Examples of GOF graphs are shown in Figures 3E and 3F .
HepTest
The selected base model consisted of a direct link E max model with Hill coefficient with a proportional error model. On the basis of plots of empirical bayesian estimates, the following covariates in full population HepTest model were selected for evaluation: study number (STUD) and albumin at screening (ALBU) for baseline and STUD and albumin at day 28 (ALB1) for the effective concentration generating 50% of effect (EC 50 ). As final model, a direct link E max pharmacodynamic model including the Hill coefficient with a proportional error model was found to fit the study data best (Fig. 2B) . E max was 43.2 s, the baseline HepTest value in the study population was 17.9 s and EC 50 was 240 µg l ¹1 (Table 4) . Plasma albumin level was selected as a covariate as it was found to influence EC 50 in the analysis. EC 50 was predicted to increase by 10.6%, or decrease by 12.9% when comparing a mean subject to the upper or lower ends of the albumin concentration range (albumin range: 3.4-5.0 g dl ¹1 ), respectively, of the demographic distribution in the data set that was used for this evaluation. Examples of GOF graphs are shown in Figures 3G and 3H .
Factor Xa activity
The selected base model consisted of a direct link inhibitory E max model with Hill coefficient, with a proportional error model. On the basis of plots of empirical bayesian estimates, the following covariates in the full population model were selected for evaluation: age (AGE) and serum glutamic oxaloacetic transaminase at screening time (SGOT) for baseline and study number (STUD) for E max . As the final model, a direct link E max pharmacodynamic model including the Hill coefficient with a proportional error model was found to fit the study data best (Fig. 2B) . E max was 0.928, the baseline Factor Xa activity value in the study population was 0.803 units ml ¹1 and the EC 50 for rivaroxaban was 221 µg l ¹1 ( Table 4) . Age was found to influence baseline levels. Baseline levels were predicted to decrease/increase by 17.32% and 23.35% when comparing a mean subject to the upper/lower ends of the demographic age distribution in the data used in this study (age range: 30-92 years). Examples of GOF graphs are shown in Figures 3I and 3J .
Simulation results: The demographics of the virtual patients with AF are reported in Table 5 . The simulations revealed that the distribution of both C max,ss and AUC 0-24,ss in Japanese patients with AF receiving a 15 mg o.d. dose of rivaroxaban would also approximate C max,ss and AUC 0-24,ss in Caucasian patients with AF receiving a 20 mg o.d. dose, albeit slightly lower in the case of C max,ss . The simulations for the 20 mg o.d. dose of rivaroxaban showed that the AUC 0-24,ss and C max,ss distribution for Japanese patients with AF would be slightly higher than AUC 0-24,ss and C max,ss distribution for Caucasian patients with AF (Fig. 4) . This might lead to a larger proportion of patients with higher C max,ss and to a lesser extent AUC 0-24,ss in Japanese patients with AF treated with 20 mg o.d. rivaroxaban compared with Caucasian patients with AF receiving 20 mg o.d. doses of rivaroxaban (Fig. 4) .
Model validation: All final pharmacokinetic and pharmacodynamic models were validated by visual inspection of GOF plots, VPC and bootstrap simulation comprehensively. GOF graphs with both population predictions and individual predictions for all models are shown in Figure 2 . While the population predictions versus dependent variable plots were equally distributed around the line of identity (Fig. 3A) , the individual predictions versus dependent variable plots showed a small bias, especially for pharmacokinetics (Fig. 3B) . The model seemed to slightly underestimate and overestimate the plasma rivaroxaban concentration at lower and higher concentrations, respectively. Because of the sparse sampling approach, it proved necessary to simplify the pharmacokinetic model in the patient population pharmacokinetic analyses to an oral, one-compartment model, resulting in a trend to underestimate C max -as theoretically expected. In addition, 1,000 non-parametric bootstrap estimations were performed on the original dataset, and all pharmacokinetic parameters were estimated based on the final model, confirming the robustness of the model and the good precision in all estimated parameters ( Table 4) . VPCs were conducted to further investigate the stability and robustness of the final models. Individual empirical bayesian estimates for pharmacokinetics were estimated using the population means and individual patient information by simulating 200 sub-problems. Ninety percent prediction intervals were then calculated and compared with the actual observations. The results of the VPCs are shown in Figures 5 and 6 . The observations were randomly distributed within the calculated 90% prediction intervals, demonstrating no obvious bias in the estimated population pharmacokinetic or pharmacodynamic parameters of the final model. Only a few observations were outside the 90% prediction interval, demonstrating that the variability of the parameters was adequately captured.
Discussion
Previously, phase I results with rivaroxaban had shown that healthy Japanese subjects (data on file) experienced a 20-40% SD, standard deviation. increase in AUC and a 20-30% increase in C max compared with healthy Caucasian subjects. 26) This phenomenon was also observed in Japanese patients receiving ximelagatran. 32, 33) The primary explanation given for the increased exposure to ximelagatran in Japanese patients was weight-and age-related decreases in renal elimination of the active metabolite melagatran. Because the Japanese population typically has a greater proportion of elderly people than most other countries, 5) and its residents generally have lower body mass indices than countries with predominantly Caucasian populations, 31) it would appear that for a given dose of a renally eliminated drug, a population of Japanese patients might be expected to experience increased exposure compared with an average population of Caucasian patients. Indeed, results from clinical pharmacology studies have revealed that renal function (i.e., renal CL), and to a lesser extent age and body weight are factors that influence the exposure level of rivaroxaban. 34, [42] [43] [44] This study used data pooled from three phase II studies of Japanese patients with AF. Study A included 10 mg and 20 mg b.i.d. rivaroxaban doses. As a total daily dose of 40 mg was considered too high for Japanese patients with AF, studies B and C were carried out to evaluate 2.5, 5 and 10 mg b.i.d and 10, 15 and 20 mg o.d. doses, respectively. These studies included patients with CHADS 2 scores of 1 and 0 as well as scores ²2, thereby providing a broad representation of patients with AF. Japanese guidelines recommend that patients with AF and a CHADS 2 score ²2 should receive oral anticoagulation therapy, and this should also be considered in patients with a CHADS 2 score of 1.
11) Moreover, these guidelines also state that oral anticoagulant therapy should be considered for patients with a CHADS 2 score of 0 in the presence of at least one the following risk factors for stroke: cardiomyopathy, age 65-74 years, female gender, coronary artery disease or thyrotoxicosis.
Analysis of data pooled from the three phase II studies of Japanese patients with AF showed that the pharmacokinetics of rivaroxaban were well described by a one-compartment model with first-order absorption and elimination with a covariate related to renal function against CL (represented by BUN). This observation is consistent with previous pharmacokinetic and pharmacodynamic studies of rivaroxaban therapy for DVT and for the prevention of venous thromboembolism after orthopaedic surgery. 27, 28, 34) The relationships between plasma concentration and pharmacodynamic parameters were best described by an E max model for Factor Xa activity and HepTest, and by linear models for PT and aPTT (by including a baseline value) using direct link models, yielding results consistent with previous pharmacokinetic and pharmacodynamic evaluations of rivaroxaban in subjects and patients from both Japanese studies (data on file) and global phase I and II venous thromboembolic prevention and DVT treatment studies. [25] [26] [27] [28] 34, 42) Hence the relationships between rivaroxaban plasma concentrations and pharmacodynamic parameters in patients with AF in Japan reported in this study are consistent with these previous findings.
Data available to date have consistently shown a dose-proportional relationship and no significant ethnicity in the relationship between rivaroxaban plasma concentrations and pharmacodynamic parameters across all ethnicities, [25] [26] [27] [28] 34, 42, 45) which was also shown in this study.
This study utilized the data from three phase II studies in Japanese patients with AF, which included a range of doses bracketing the 20 mg o.d. dose of rivaroxaban selected for the global ROCKET AF trial. However, in practice, Japanese clinicians prefer to use lower doses of warfarin, even in patients under 70 years of age, primarily driven by concerns about bleeding. Recent registry data for Japanese patients with AF showed that 66% of patients receiving warfarin had an INR within the range 1.6-2.6 (mean for all patients 1.9), irrespective of age. 14) Results from the current modelling study indicate that the simulated steady-state exposure of Japanese patients with AF treated with rivaroxaban 15 mg o.d. approximates both the C max,ss and AUC 0-24,ss achieved in simulated Caucasian patients with AF treated with rivaroxaban 20 mg o.d. 34) The finding that the simulation of the 20 mg o.d. dose of rivaroxaban in Japanese patients with AF achieved slightly higher pharmacokinetic parameters than in Caucasian patients with AF treated with the same dose is the same tendency of the minimal effect of age and body weight seen previously. 34, 42, 43) This difference in exposure levels between Japanese and Caucasian might include some ethnic factors which cannot be explained from only age, body weight and renal function modelled in Japanese or Caucasian population pharmacokinetic models. 34) This could be because the information obtained from sparse sampling data in Phase II trials might be limited.
In addition, the 20 mg o.d. dose for Japanese patients would carry the risk of more patients including "fragile" patients who are very old and/or have a much lower body weight, though experiencing higher C max,ss and to a lesser extent AUC 0-24,ss compared with Caucasian patients with AF receiving a 20 mg o.d. dose in these simulation results. Considering these factors together, the 15 mg o.d. dose for Japanese patients with AF appeared to provide a greater margin to allow for potential individual variability, particularly in the context of preferred lower anticoagulant doses in Japanese clinical practice. 11, 14) These results provide important support for the selection of 15 mg o.d. as the dose of rivaroxaban to be evaluated for the prevention of stroke in Japanese patients with AF, integrating both ethnic pharmacokinetic effects using population pharmacokinetic and pharmacodynamic modeling (likely explained by a lower distribution of body mass indices) as well as the clinical practice differences in Japan, where the preference is to utilize lower levels of anti- coagulation. The rivaroxaban dose was lowered to 10 mg o.d. in patients with renal impairment in J-ROCKET AF, in a similar manner to the global ROCKET AF trial. 23) Further PK-PD sampling and also population PK-PD evaluation were planned in the ROCKET AF and J-ROCKET AF trial to confirm whether this dose setting is appropriate from a PK-PD point of view.
